A Delaware federal court has handed Guardant Health (GH) a $245.2 million final judgment for willful DNA-sequencing patent infringement, imposing ongoing royalties on products that generated roughly 90% of the company’s revenue during the infringement period.
The ruling introduces a 6% royalty drag on U.S. sales of 11 products – including flagship tests Guardant360 CDx, Guardant Reveal, and the Shield cancer screen – that will run until the contested patents expire in March 2033, creating a sustained headwind for earnings and competitive positioning in the liquid-biopsy market.
Key Takeaways
- Court orders $245.2 million total, including $119.4 million in accrued royalties.
- 6% royalty on 11 products continues until March 2033 patent expiry.
- Infringed products covered ~90% of Guardant’s revenue in dispute period.
Detailed Analysis: What the Judgment Comprises
The U.S. District Court for the District of Delaware entered final judgment on August 21, upholding a November 2023 jury verdict that found Guardant had willfully infringed two patents owned by TwinStrand Biosciences and licensed from the University of Washington 1. The court rejected Guardant’s post-trial motions seeking to overturn the verdict or obtain a new trial.
The $245.2 million award breaks down as follows: $83.4 million in original damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties, and $22.9 million in pre- and post-judgment interest. The ongoing 6% royalty rate on U.S. sales represents a structural cost that analysts will need to model into Guardant’s margin assumptions for the remainder of the decade.
Market Context & Competitive Positioning
Guardant competes in the high-growth liquid-biopsy sector alongside players such as Exact Sciences and Illumina-backed ventures, where intellectual-property moats increasingly define competitive durability. A royalty obligation tied to roughly 90% of revenue is a materially different cost structure than a one-time settlement, and it could complicate Guardant’s pricing power and partnership negotiations in an already capital-intensive space.
TwinStrand’s Duplex Sequencing technology – developed at the University of Washington – is designed to detect rare genetic mutations with greater accuracy than conventional DNA sequencing methods and is deployed in cancer research, diagnostics, and drug development 1. The breadth of products found to infringe underscores how foundational the disputed methodology is to Guardant’s current commercial portfolio.
Outlook & Management Quote
TwinStrand framed the outcome as a full vindication of its intellectual property.
“The court’s final judgment confirms what the jury found in 2023 – that Guardant willfully used our patented technology without authorization,” TwinStrand said in its Monday statement, as reported by Reuters.
Guardant had argued for overturn or a new trial, but both requests were denied, and the court simultaneously upheld the validity of the patent claims at issue – closing off a key avenue for further challenge at the district-court level 1. An appeal to the Federal Circuit remains a potential next step, though that path would likely extend uncertainty for investors for another year or more.
Conclusion
For macro and sector investors tracking biotech IP risk, the Guardant ruling is a cautionary data point: a 6% perpetual royalty on core revenue-generating assets through 2033 is meaningful enough to pressure margins and potentially affect the company’s attractiveness as an M&A target or partner. Whether Guardant pursues an appeal or negotiates a licensing restructuring will be the key variable to watch in coming quarters.
Not investment advice. For informational purposes only.
References
1Reuters (August 24, 2026). “U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute”. Reuters. Retrieved August 24, 2026.